People: Zalicus Inc (ZLCS.OQ)
ZLCS.OQ on NASDAQ Stock Exchange Capital Market
0.64USD
4:00pm EDT
0.64USD
4:00pm EDT
Price Change (% chg)
$0.16 (+32.64%)
$0.16 (+32.64%)
Prev Close
$0.48
$0.48
Open
$0.48
$0.48
Day's High
$0.64
$0.64
Day's Low
$0.48
$0.48
Volume
904,057
904,057
Avg. Vol
112,574
112,574
52-wk High
$1.54
$1.54
52-wk Low
$0.43
$0.43
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Frank Haydu |
64 | 2009 | Independent Chairman of the Board |
Mark Corrigan |
55 | 2010 | President, Chief Executive Officer, Director |
Justin Renz |
40 | 2012 | Chief Financial Officer, Executive Vice President - Finance, Treasurer |
Jason Cole |
39 | 2012 | Executive Vice President - Corporate Development, General Counsel, Secretary |
Sally Crawford |
59 | 2007 | Independent Director |
William Hunter |
49 | 2009 | Independent Director |
Michael Kauffman |
2006 | Independent Director | |
James O'Shea |
62 | 2007 | Independent Director |
Biographies
| Name | Description |
|---|---|
Frank Haydu |
Mr. Frank Haydu is Independent Chairman of the Board of Zalicus Inc., since February 2009. He is Director since August 2004. Mr. Haydu is a professional director and consultant to public and private businesses. Mr. Haydu currently serves as a director and Chairman of the Audit Committee of iParty Corp., a publicly held retail chain, and several private companies. In the past five years, Mr. Haydu has also served on the board of directors of Moldflow Corporation, a publicly traded injection molding software company. Mr. Haydu holds a B.A. in economics from Muhlenberg College. |
Mark Corrigan |
Dr. Mark H. N. Corrigan, M.D., is President, Chief Executive Officer, Director of Zalicus Inc. He is Director since December 2009. Dr. Corrigan has served as President and Chief Executive Officer of Zalicus since January 2010. Dr. Corrigan was Executive Vice President, Research & Development of Sepracor Inc., a publicly traded pharmaceutical company, from April 2003 until December 2009. Prior to joining Sepracor Inc., Dr. Corrigan spent 10 years with Pharmacia & Upjohn, a publicly traded pharmaceutical company acquired by Pfizer, Inc. in 2002, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Dr. Corrigan serves on the board of directors of Cubist Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. Prior to joining the pharmaceutical industry, Dr. Corrigan spent five years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and subsequently received specialty training in Psychiatry at Cornell and Maine Medical Center. |
Justin Renz |
Mr. Justin A. Renz is Chief Financial Officer, Executive Vice President - Finance, Treasurer of Zalicus Inc. Mr. Renz joined Zalicus in September 2006 as Vice President, Finance and Treasurer, was appointed as its Senior Vice President, Chief Financial Officer and Treasurer in July 2009 and has served as its Executive Vice President, Finance and Treasurer since March 2012. From August 2005 to September 2006, Mr. Renz was Director, Accounting and Financial Operations at EMD Serono, Inc., a publicly-traded biopharmaceutical company. From 2002 to 2005, he was Senior Director, Global Accounting and Finance at Coley Pharmaceutical Group, a publicly-traded biopharmaceutical company acquired by Pfizer in 2007, and has also held financial and accounting positions at ArQule, Inc., Millipore Corporation and Arthur Andersen LLP. Mr. Renz is a certified public accountant and holds a B.A. in Economics/Accounting from the College of the Holy Cross, a Masters in the Science of Taxation from Northeastern University and an M.B.A. from Suffolk University. |
Jason Cole |
Mr. Jason F. Cole, Esq., is Executive Vice President - Corporate Development, General Counsel and Secretary of Zalicus Inc., since March 2012. Mr. Cole joined Zalicus as its Senior Vice President, General Counsel and Secretary in January 2006, was appointed as its Senior Vice President, Corporate Development, General Counsel and Secretary in September 2011. From 1999 to 2006, Mr. Cole was a corporate and securities attorney at Ropes & Gray LLP. Mr. Cole holds an A.B. in Government from Dartmouth College and a J.D. from Columbia University School of Law. |
Sally Crawford |
Ms. Sally W. Crawford is Independent Director of Zalicus Inc., since June 2007. From April 1985 until January 1997, Ms. Crawford served as Chief Operating Officer of Healthsource, Inc., a publicly traded managed care organization headquartered in New Hampshire. During her tenure at Healthsource, Inc., Ms. Crawford held a variety of positions and responsibilities, including that company’s Northern Region operations and marketing efforts. Since January 1997, Ms. Crawford has been a healthcare consultant. Ms. Crawford serves on the board of directors for Hologic, Inc., a publicly traded manufacturer and supplier of medical equipment, Exact Sciences Corporation, a publicly held molecular diagnostics company, Insulet Corporation, a publicly held medical device company, Universal American Corp., a publicly held healthcare company and served private healthcare companies. In the past five years, Ms. Crawford has also served on the board of directors of Cytyc Corporation, a publicly traded medical device company and Chittenden Corporation, a publicly traded financial institution. Ms. Crawford holds a B.A. in English from Smith College and an M.S. in communications from Boston University. |
William Hunter |
Dr. William Hunter, M.D. is Independent Director of Zalicus Inc., since December 2009. Dr. Hunter founded Angiotech Pharmaceuticals, Inc., a publicly traded pharmaceutical and medical device company in November 1992, served as a director and its President and Chief Executive Officer until October 2011. Dr. Hunter also serves as a director of Cardiome Pharma Corp., a publicly traded drug development and research company. In January of 2011, Angiotech voluntarily filed under the Canada Companies’ Creditors Arrangement Act the (“CCAA”) to pursue a restructuring supervised by the Supreme Court of British Columbia, and also voluntarily filed a petition under Chapter 15 of the United States Bankruptcy Code to obtain recognition and enforcement in the United States of the restructuring being pursed under the CCAA proceedings. The Angiotech restructuring was completed in May 2011. Dr. Hunter holds a B.Sc. from McGill University, and an M.Sc. and M.D. from the University of British Columbia. |
Michael Kauffman |
Dr. Michael G. Kauffman, M.D., Ph.D., is Independent Director of Zalicus Inc., since June 2006. Dr. Kauffman has been the President and Chief Executive Officer of Karyopharm Therapeutics Inc. since January 2011 and has been a Science Advisor to Bessemer Venture Partners since 2008. Dr. Kauffman was the Chief Medical Officer of Onyx Pharmaceuticals from January 2010 until December 2010. Dr. Kauffman was the Chief Medical Officer of Proteolix, Inc., a privately held pharmaceutical company, from April 2009 until November 2009, when it was acquired by Onyx. Dr. Kauffman was the President and Chief Executive Officer of EPIX Pharmaceuticals, Inc., a publicly traded biotechnology company that underwent liquidation proceedings in 2009, until July 2008. Dr. Kauffman joined Predix Pharmaceuticals, Inc., the predecessor to EPIX, in September 2002, as President and Chief Executive Officer. From 1997 to 2002, he held a number of senior medical and program leadership positions at Millennium Pharmaceuticals, Inc., then a publicly held biotechnology company, including Vice President, Medicine and VELCADE Program Leader as well as co-founder and Vice President of Medicine at Millennium Predictive Medicine, a wholly-owned subsidiary of Millennium. Dr. Kauffman also served as Medical Director at Biogen Corporation (now Biogen Idec Inc., a publicly traded biotechnology company). In the past five years, Dr. Kauffman has also served on the board of directors of EPIX and Bioenvision, a publicly traded biotechnology company. Dr. Kauffman received an M.D. and Ph.D. in molecular biology and biochemistry from Johns Hopkins and holds a B.A. in biochemistry from Amherst College. Dr. Kauffman trained in Internal Medicine at Beth Israel Deaconess and Massachusetts General Hospitals. |
James O'Shea |
Mr. W. James O'Shea is Independent Director of Zalicus Inc., since June 2007. From April to August 2007, Mr. O’Shea served as Vice Chairman at Sepracor Inc., then a publicly held pharmaceutical company. From October 1999 to March 2007, Mr. O’Shea was President and Chief Operating Officer at Sepracor, where he was responsible for building that organization’s commercial infrastructure. Prior to Sepracor, Mr. O’Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc, a publicly held biopharmaceutical company. While at Zeneca, he also held several management positions of increasing responsibility in international sales and marketing in the U.S. and U.K. Mr. O’Shea is past Chairman of the National Pharmaceutical Council and serves on the board of directors of BTG plc, a public specialty pharmaceutical company, MAP Pharmaceuticals, Inc., a publicly traded pharmaceutical company, and several other private biopharmaceutical companies. In the past five years, Mr. O’Shea has also served on the board of directors of Penwest Pharmaceutical Co., a publicly traded specialty pharmaceutical company. Mr. O’Shea is a graduate of Liverpool Lord Byron University, where he received an honors degree in applied physics from the Institute of Physics. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Frank Haydu |
-- |
Mark Corrigan |
1,744,980 |
Justin Renz |
795,328 |
Jason Cole |
815,212 |
Sally Crawford |
-- |
William Hunter |
-- |
Michael Kauffman |
-- |
James O'Shea |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Frank Haydu |
0 | 0 |
Mark Corrigan |
0 | 0 |
Justin Renz |
0 | 0 |
Jason Cole |
251,269 | 381,234 |
Sally Crawford |
0 | 0 |
William Hunter |
0 | 0 |
Michael Kauffman |
0 | 0 |
James O'Shea |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
CORRIGAN MARK H N |
112,850 | $0.77 |
CORRIGAN MARK H N |
250,000 | $0.00 |
GALLEN CHRISTOPHER |
350,000 | $0.00 |
COLE JASON F |
2,420 | $1.09 |
CORRIGAN MARK H N |
68,105 | $1.14 |
MPM BIOVENTURES III L L C |
738,807 | $1.03 |
MPM BIOVENTURES III L L C |
78,000 | $1.02 |
MPM BIOVENTURES III L L C |
203,200 | $1.02 |
MPM BIOVENTURES III L L C |
252,000 | $1.03 |
MPM BIOVENTURES III L L C |
70,100 | $1.02 |
MPM BIOVENTURES III L L C |
425,000 | $1.03 |
MPM BIOVENTURES III L L C |
34,817 | $1.02 |
MPM BIOVENTURES III L L C |
19,644 | $1.02 |
EVNIN LUKE BASIL |
39,700 | $1.02 |
MPM BIOVENTURES III L L C |
39,700 | $1.02 |
MPM BIOVENTURES III L L C |
5,000 | $1.02 |
EVNIN LUKE BASIL |
5,000 | $1.02 |
MPM BIOVENTURES III L L C |
131,800 | $1.02 |
MPM BIOVENTURES III L L C |
206,500 | $1.02 |
EVNIN LUKE BASIL |
230,000 | $1.04 |
MPM BIOVENTURES III L L C |
230,000 | $1.04 |
EVNIN LUKE BASIL |
275,200 | $1.03 |
MPM BIOVENTURES III L L C |
275,200 | $1.03 |
EVNIN LUKE BASIL |
170,000 | $1.02 |
EVNIN LUKE BASIL |
33,124 | $1.02 |

